Phase II Study of S-1 and Docetaxel for Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Cancer Chemotherapy and Pharmacology - Germany
doi 10.1007/s00280-009-1239-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Pcn176 - A Cost-Effectiveness Analysis of Atezolizumab Versus Docetaxel for Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Belgium

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2016English

Phase II Study of Ramucirumab and Docetaxel for Previously Treated Non-Small Cell Lung Cancer Patients With Malignant Pleural Effusion: Protocol of PLEURAM Study

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2019English

Phase I/Ii Study of Gefitinib (Iressa®) and Vorinostat (IVORI) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2015English

Phase II Study of Docetaxel Alternating With Cisplatin in Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer

Anti-Cancer Drugs
Cancer ResearchOncologyPharmacology
2000English

Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (Nsclc): A Network Meta-Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Phase I and Pharmacokinetic Study of Pemetrexed Plus Cisplatin in Chemonaive Patients With Locally Advanced or Metastatic Malignant Pleural Mesothelioma or Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2009English

P3.04-17 Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-37 Phase II Study of Amrubicin Plus Erlotinib in Previously Treated, Advanced Non-Small Cell Lung Cancer Patients With Wild-Type EGFR: TORG 1320

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy